Posts

ISB has won a 2025 AWS Imagine Grant to advance Tarpon, a generative AI platform that generates digital fingerprints of T cell receptors. By linking immune signatures to genomic and clinical data, Tarpon enables rapid discovery and the design of targeted therapies.

At a recent virtual town hall, leaders of the Pacific Northwest RECOVER hub shared what they’ve learned so far about long COVID — from symptom trajectories and genetic risk to early trial results and upcoming studies — and answered questions from participants about risk factors, persistent symptoms and what comes next.

Researchers from the NIH-funded RECOVER study shared new insights on the risks of Long COVID, autoimmune links, and upcoming clinical trials during ISB’s July Town Hall.

In a Research Roundtable presentation and Q&A, ISB President Dr. Jim Heath shared how his team is using generative AI to unlock new understanding of human immunity, and how these discoveries could help predict disease severity, improve cancer therapies, and more.

Co-Author Craig Mundie and ISB’s Dr. Jim Heath discuss AI’s rapid evolution, ethical considerations, and potential to revolutionize science and society in a compelling Town Hall event.

ISB researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.